BTL has published a peer-reviewed clinical study on ExoTMS™ technology, highlighting significant improvements in mental wellbeing following treatment. The clinical trial, published in the Journal of Psychiatry and Psychiatric Disorders, evaluated the effects of ExoTMS™ across 33 adult participants with a range of baseline wellbeing and reported consistent improvements in psychological health, comfort, and overall satisfaction.
Participants underwent four treatments targeting the left dorsolateral prefrontal cortex (DLPFC) using the EXOMIND device (BTL Industries, Boston, MA, USA) with ExoTMS™ Technology. The individual treatments were spaced 5–10 days apart. The validated Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) was administered at baseline, after the final treatment, and at both follow-up visits to assess post-treatment changes in mental well-being.
Among participants diagnosed with depression, at three months, over 80% reported the treatments improved their mental wellness and mood, feeling less depressed and stressed, being in a good mood after the treatments, thinking more positively, and finding it easier to fall asleep. Additionally, 90.9% of subjects found the treatment comfortable. The average score on the Numerical Rating Scale for pain was 0.2 ± 0.8 out of 10 points, indicating the treatment was painless.
While further controlled studies are warranted, these early findings highlight the strong potential of ExoTMS™ in supporting mental wellness.
FURTHER INFORMATION
BTL Aesthetics
https://btlaesthetics.com/en/for-providers/exomind-providers
